the Prevention of Bone Marrow Suppression Caused by Chemotherapy in Advanced NSCLC With Trilaciclib - Trial NCT06370416
Access comprehensive clinical trial information for NCT06370416 through Pure Global AI's free database. This Phase 2 trial is sponsored by Henan Cancer Hospital and is currently Not yet recruiting. The study focuses on Non-small Cell Lung Cancer. Target enrollment is 40 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Henan Cancer Hospital
Timeline & Enrollment
Phase 2
Apr 30, 2024
Dec 31, 2025
Primary Outcome
The incidence of grade ≥ 3 neutropenia during chemotherapy treatment
Summary
This study is a single arm, exploratory clinical study aimed at evaluating the efficacy and
 safety of tralazili before chemotherapy in patients with NSCLC.After pathological diagnosis
 of non-small cell lung cancer(NSCLC), 40 eligible subjects who met the inclusion criteria
 were screened and given a treatment regimen of trilaciclib before chemotherapy, after signing
 informed consent.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06370416
Non-Device Trial